The Canadian Drug Manufacturers Association, which represents thegeneric industry, has said it no longer believes that talks with the federal government to change drug market regulations are being conducted in good faith.
The claim comes after it was revealed that despite pledges to help the generics industry made days after publication of the parliamentary committee review of drug legislation (Marketletter May 5), federal Industry Ministry staff were actually seeking ways to boost patent protection for brand-name drugmakers. "It seems that Industry Canada's policies are for sale, but only to wealthy foreign multinational companies," said CDMA president Brenda Drinkwalter, in a letter to federal Industry Minister John Manley.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze